Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis

Leukemia and Lymphoma

Volumn 49, Issue 1, 2008, Pages 36-41

  Gertz, Morie ^a   Lacy, Martha ^a   Dispenzieri, Angela ^a   Hayman, Suzanne ^a   Kumar, Shaji ^a   Buadi, Francis ^a   Leung, Nelson ^a   Litzow, Mark ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Multiple myeloma; Restrictive cardiomyopathy; Stem cell transplantation; Troponin T

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; TROPONIN T;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; DEATH; DRUG DOSE REDUCTION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART AMYLOIDOSIS; HUMAN; KAPLAN MEIER METHOD; KIDNEY AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; BIOLOGICAL MARKERS; CAUSE OF DEATH; ELECTROCARDIOGRAPHY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TROPONIN T;

EID: 38549110552     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701684518     Document Type: Article

References (43)

1. Comenzo, R. L. (2006) Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma, 7, pp. 182-185.
2. Kyle, R. A., Gertz, M. A., Greipp, P. R., Witzig, T. E., Lust, J. A. and Lacy, M. Q. (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med, 336, pp. 1202-1207.
3. Skinner, M., Anderson, J., Simms, R., Falk, R., Wang, M. and Libbey, C. (1996) Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med, 100, pp. 290-298.
4. Dhodapkar, M. V., Hussein, M. A., Rasmussen, E., Solomon, A., Larson, R. A., Crowley, J. J. and United States Intergroup Trial Southwest Oncology Group (2004) Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: Results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood, 104, pp. 3520-3526.
5. Sanchorawala, V., Wright, D. G., Rosenzweig, M., Finn, K. T., Fennessey, S. and Zeldis, J. B. (2007) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood, 109, pp. 492-496.
6. Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F. and Caccialanza, R. (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105, pp. 2949-2951.
7. Dispenzieri, A., Lacy, M. Q., Rajkumar, S. V., Geyer, S. M., Witzig, T. E. and Fonseca, R. (2003) Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid, 10, pp. 257-261.
8. Dispenzieri, A., Lacy, M. Q., Zeldenrust, S. R., Hayman, S. R., Kumar, S. K. and Geyer, S. M. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, pp. 465-470.
9. Skinner, M., Sanchorawala, V., Seldin, D. C., Dember, L. M., Falk, R. H. and Berk, J. L. (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med, 140, pp. 85-93.
10. Comenzo, R. L. (2007) Current and emerging views and treatments of systemic immunoglobulin light-chain (AL) amyloidosis. Contrib Nephrol, 153, pp. 195-210.
11. Vesole, D. H., Perez, W. S., Akasheh, M., Boudreau, C., Reece, D. E., Bredeson, C. N. and Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research (2006) High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc, 81, pp. 880-888.
12. Goodman, H. J., Gillmore, J. D., Lachmann, H. J., Wechalekar, A. D., Bradwell, A. R. and Hawkins, P. N. (2006) Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol, 134, pp. 417-425.
13. Bahlis, N. J. and Lazarus, H. M. (2006) Multiple myeloma-associated AL amyloidosis: Is a distinctive therapeutic approach warranted?. Bone Marrow Transplant, 38, pp. 7-15.
14. Perz, J. B., Rahemtulla, A., Giles, C., Szydlo, R. M., Davis, J. and Gopaul, D. (2006) Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplant, 37, pp. 937-943.
15. Chow, L. Q., Bahlis, N., Russell, J., Chaudhry, A., Morris, D. and Brown, C. (2005) Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: The Calgary BMT Program experience. Bone Marrow Transplant, 36, pp. 591-596.
16. Mollee, P. N., Wechalekar, A. D., Pereira, D. L., Franke, N., Reece, D. and Chen, C. (2004) Autologous stem cell transplantation in primary systemic amyloidosis: The impact of selection criteria on outcome. Bone Marrow Transplant, 33, pp. 271-277.
17. Saba, N., Sutton, D., Ross, H., Siu, S., Crump, R. and Keating, A. (1999) High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant, 24, pp. 853-855.
18. Jantunen, E., Itala, M., Lehtinen, T., Kuittinen, O., Koivunen, E. and Leppa, S. (2006) Early treatment-related mortality in adult autologous stem cell transplant recipients: A nation-wide survey of 1482 transplanted patients. Eur J Haematol, 76, pp. 245-250.
19. Kristen, A. V., Meyer, F. J., Perz, J. B., Schonland, S. O., Hundemer, M. and Hegenbart, U. (2005) Risk stratification in cardiac amyloidosis: novel approaches. Transplantation, 80, pp. S151-S155.
20. Gono, T., Matsuda, M., Shimojima, Y., Ishii, W., Koyama, J. and Sakashita, K. (2004) VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid, 11, pp. 245-256.
21. Dispenzieri, A., Kyle, R. A., Gertz, M. A., Therneau, T. M., Miller, W. L. and Chandrasekaran, K. (2003) Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet, 361, pp. 1787-1789.
22. Wallace, T. W., Abdullah, S. M., Drazner, M. H., Das, S. R., Khera, A. and McGuire, D. K. (2006) Prevalence and determinants of troponin T elevation in the general population. Circulation, 113, pp. 1958-1965.
23. Comenzo, R. L., Vosburgh, E., Falk, R. H., Sanchorawala, V., Reisinger, J. and Dubrey, S. (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood, 91, pp. 3662-3670.
24. Comenzo, R. L. (2007) Managing systemic light-chain amyloidosis. J Natl Compr Cancer Net, 5, pp. 179-187.
25. Palladini, G., Perfetti, V., Obici, L., Caccialanza, R., Semino, A. and Adami, F. (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 103, pp. 2936-2938.
26. Wechalekar, A. D., Goodman, H. J., Lachmann, H. J., Offer, M., Hawkins, P. N. and Gillmore, J. D. (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 109, pp. 457-464.
27. Wechalekar, A. D., Gillmore, J., Lachmann, H. J., Offer, M. and Hawkins, P. N. (2006) Efficacy and safety of bortezomib in systemic AL amyloidosis: A preliminary report. Blood (Suppl.), 108, p. 129.
28. Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L. and Hermine, O. (2005) Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: Results of the French Multicentric Randomized Trial (MAG and IFM Intergroup). Blood (Suppl.), 106, p. 421.
29. Dispenzieri, A., Lacy, M. Q., Kyle, R. A., Therneau, T. M., Larson, D. R. and Rajkumar, S. V. (2001) Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol, 19, pp. 3350-3356.
30. Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Hayman, S. R. and Kumar, S. (2007) Transplantation for amyloidosis. Curr Opin Oncol, 19, pp. 136-141.
31. Dispenzieri, A., Kyle, R. A., Lacy, M. Q., Therneau, T. M., Larson, D. R. and Plevak, M. F. (2004) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: A case-control study. Blood, 103, pp. 3960-3963.
32. Seldin, D. C., Anderson, J. J., Sanchorawala, V., Malek, K., Wright, D. G. and Quillen, K. (2004) Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood, 104, pp. 1888-1893.
33. Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Gastineau, D. A., Chen, M. G. and Ansell, S. M. (2002) Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med, 113, pp. 549-555.
34. Dispenzieri, A., Lacy, M. Q., Katzmann, J. A., Rajkumar, S. V., Abraham, R. S. and Hayman, S. R. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 107, pp. 3378-3383.
35. Sanchorawala, V., Wright, D. G., Quillen, K., Fisher, C., Skinner, M. and Seldin, D. C. (2005) Early serum free light chain responses following high-dose melphalan and stem cell transplantation for AL amyloidosis predict treatment outcomes. Blood (Suppl.), 106, p. 1160.
36. Leung, N., Leung, T. R., Cha, S. S., Dispenzieri, A., Lacy, M. Q. and Gertz, M. A. (2005) Excessive fluid accumulation during stem cell mobilization: A novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood, 106, pp. 3353-3357.
37. Porrata, L. F., Gertz, M. A., Litzow, M. R., Lacy, M. Q., Dispenzieri, A. and Inwards, D. J. (2005) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res, 11, pp. 1210-1218.
38. Palladini, G., Campana, C., Klersy, C., Balduini, A., Vadacca, G. and Perfetti, V. (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation, 107, pp. 2440-2445.
39. Dispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F. and Therneau, T. M. (2004) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 104, pp. 1881-1887.
40. Dispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F. and Therneau, T. M. (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol, 22, pp. 3751-3757.
41. Leung, N., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Kumar, S. and Gertz, M. A. (2006) Risk factors of treatment related mortality during autologous stem cell transplant in patients with light chain associated amyloidosis (AL). Blood (Suppl.), 108, p. 3082.
42. Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Ansell, S. M., Elliott, M. A. and Gastineau, D. A. (2004) Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant, 34, pp. 1025-1031.
43. Comenzo, R. L. and Gertz, M. A. (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99, pp. 4276-4282.